Teva Pharmaceutical Industries vs Zoetis
TEVA and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TEVA and ZTS compare
Teva Pharmaceutical Industries is the larger company, worth 1.5 times as much as Zoetis ($48.3B against $32.9B).
On earnings, Zoetis is cheaper: it trades at 13.1× trailing earnings, against 69.1× for Teva Pharmaceutical Industries.
Zoetis grew revenue faster over the last twelve months (1.5% versus −15.2% for Teva Pharmaceutical Industries).
Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with 5.0% at Teva Pharmaceutical Industries.
Zoetis pays a dividend yielding 2.6%; Teva Pharmaceutical Industries does not pay one.
Zoetis scores higher on the StockData Score (17 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TEVA | ZTS |
|---|---|---|
| Size and price | ||
| Market cap | $48.3B | $32.9B |
| Share price | $41.47 | $79.72 |
| Change, 1 year | 110% | −44.6% |
| Change, 5 years | 354% | −63.2% |
| Beta (5Y) | 0.99 | 0.78 |
| Employees | 34K | 15K |
| StockData Score | ||
| Total score | 7 | 17 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 | 5 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 69.1× | 13.1× (better) |
| P/S | 3.4× (better) | 3.5× |
| P/B | 6.2× (better) | 10.5× |
| EV/EBITDA | 19.0× | 10.1× (better) |
| P/FCF | 35.8× | 14.2× (better) |
| PEG | – | 1.28 |
| FCF yield | 2.8% | 7.0% (better) |
| Fair value | $18.65 | $152.11 |
| Margin of safety | −122% | 47.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −15.2% | 1.5% (better) |
| Revenue growth, 5Y average | 0.71% | 7.2% (better) |
| Net income growth (TTM) | – | 0.96% |
| EPS growth (TTM) | – | 5.6% |
| EPS growth, 5Y average | – | 12.0% |
| Profitability | ||
| Gross margin | 64.4% | 71.5% (better) |
| Operating margin | 11.4% | – |
| Net margin | 5.0% | 27.5% (better) |
| FCF margin | 9.6% | 24.3% (better) |
| Return on equity | 9.7% | 64.4% (better) |
| Return on invested capital | 23.0% | – |
| Financial health | ||
| Debt / equity | 0.58 (better) | 2.87 |
| Net debt / EBITDA | 0.33 (better) | 1.85 |
| Current ratio | 0.88 | 3.08 (better) |
| Altman Z-score | 0.84 | 3.99 (better) |
| Piotroski F-score | 8 | 8 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.6% |
| Years of dividend growth | – | 13 |
| Dividend growth, 5Y average | – | 19.0% |
| Buyback yield | – | 11.1% |
| Shareholder yield | 0.00% | 13.7% (better) |
| Ownership | ||
| Held by institutions | – | 96.1% |
| Held by insiders | 0.43% | 0.08% |
| Insider net buying, 12 months | −$113M | −$1.7M (better) |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 2.6% | 4.5% |
Go deeper
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
- ZTS stock overview
- ZTS income statement
- ZTS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.